<DOC>
	<DOCNO>NCT01092507</DOCNO>
	<brief_summary>The purpose study compare single dose Japanese encephalitis ( JE ) chimeric virus vaccine ( JE-CV ) single dose SA14-14-2 live vaccine primary vaccination infant toddler . Primary Objective : - To demonstrate non-inferiority antibody response 28 day vaccine administration one dose JE CV ( administer Day 0 ) compare antibody response one dose SA14-14-2 control vaccine ( administer Day 0 ) . Secondary Objectives : - To describe immune response JE vaccine group JE-CV virus SA14-14-2 virus single dose JE CV single dose SA14-14-2 vaccine - To describe safety profile vaccinate subject 28 day serious adverse event ( SAEs ) 6 month vaccination . - To describe related SAEs death 6 month 12-month follow-up .</brief_summary>
	<brief_title>A Study Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine Infants Toddlers</brief_title>
	<detailed_description>All participant receive one injection randomize vaccine Day 0 . Follow-up continue 12 month vaccination .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Aged 9 18 month day inclusion In good general health , without significant medical history Provision inform consent form sign least one parent legally acceptable representative , least one independent witness require local regulation Subject parent/legally acceptable representative able attend schedule visit comply trial procedure Completion vaccination accord national immunization schedule . Exclusion Criteria : Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede first trial vaccination Planned participation another clinical trial present trial period Known suspect congenital acquire immunodeficiency , immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy Known systemic hypersensitivity vaccine component history lifethreatening reaction vaccine contain substance Chronic illness stage could interfere trial conduct completion , opinion Investigator Receipt blood bloodderived product past 3 month might interfere assessment immune response Previous vaccination flavivirus disease , include Japanese encephalitis ( JE ) Administration antiviral within 2 month precede first vaccination 4 week follow last trial vaccination Month 3 Receipt vaccine 4 week precede first trial vaccination Planned receipt vaccine inclusion 4 week follow last trial vaccination Planned receipt Japanese encephalitis vaccine course study History central nervous system disorder disease , include seizure History flavivirus infection ( confirm either clinically , serologically microbiologically ) Febrile illness ( temperature ≥ 38°C ) moderate severe acute illness/infection day vaccination , accord Investigator judgment .</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Encephalitis</keyword>
	<keyword>Japanese Encephalitis</keyword>
	<keyword>Japanese Encephalitis Vaccines</keyword>
	<keyword>Infant</keyword>
</DOC>